HIGHLIGHTS
- who: Melinda A. Pruis from the Received: , October , Revised: , April , Accepted: , May , Published online: , May , Published on Behalf of CR UK have published the research: Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing, in the Journal: (JOURNAL)
- what: The study shows that the dropout rate of molecular pre-screening was relatively low in comparison to other trials with similar patient populations, as the authors combined stringent patient selection based on performance scores and laboratory values with an acceptable TAT . The authors show that multiplex immunofluorescence is . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.